大卫·A·里克斯 David A Ricks — 礼来 CEO
FORTUNE 500 #336

大卫·A·里克斯

David A Ricks

礼来 (Eli Lilly)

领导U.S.大型Pharmaceuticals企业运营

广告

专业领域

医疗健康管理 生命科学

Healthcare management, life sciences

核心贡献

领导U.S.大型Pharmaceuticals企业运营

Leading large-scale Pharmaceuticals operations in U.S.

最新观点

  • Eli Lilly(2026年Q3业绩新闻稿,SEC EX-99.1) · 2026-10-29 阅读原文

    礼来董事长兼CEO里克斯在2026年Q3业绩中表示,公司再次实现强劲季度并上调全年指引:营收同比增长39%至244亿美元,主要由Mounjaro与Zepbound的全球需求、Foundayo全球上市、美国肥胖症护理覆盖扩大以及肿瘤、免疫、神经科学新产品翻倍增长驱动;为支撑长期增长,公司持续投资制药与技术能力。

    Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities.

广告